ZA966425B - Method of detecting lung disease. - Google Patents

Method of detecting lung disease.

Info

Publication number
ZA966425B
ZA966425B ZA9606425A ZA966425A ZA966425B ZA 966425 B ZA966425 B ZA 966425B ZA 9606425 A ZA9606425 A ZA 9606425A ZA 966425 A ZA966425 A ZA 966425A ZA 966425 B ZA966425 B ZA 966425B
Authority
ZA
South Africa
Prior art keywords
lung
acceptable salt
sample
mucus
composition
Prior art date
Application number
ZA9606425A
Other languages
English (en)
Inventor
Jr Richard C Boucher
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of ZA966425B publication Critical patent/ZA966425B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA9606425A 1995-07-31 1996-07-29 Method of detecting lung disease. ZA966425B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/509,052 US5628984A (en) 1995-07-31 1995-07-31 Method of detecting lung disease

Publications (1)

Publication Number Publication Date
ZA966425B true ZA966425B (en) 1997-02-19

Family

ID=24025091

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606425A ZA966425B (en) 1995-07-31 1996-07-29 Method of detecting lung disease.

Country Status (17)

Country Link
US (4) US5628984A (cg-RX-API-DMAC7.html)
EP (1) EP0841900B1 (cg-RX-API-DMAC7.html)
JP (2) JP3623237B2 (cg-RX-API-DMAC7.html)
KR (1) KR100283306B1 (cg-RX-API-DMAC7.html)
CN (1) CN1121441C (cg-RX-API-DMAC7.html)
AT (1) ATE276740T1 (cg-RX-API-DMAC7.html)
AU (1) AU705528B2 (cg-RX-API-DMAC7.html)
BR (1) BR9610059A (cg-RX-API-DMAC7.html)
CA (1) CA2226892A1 (cg-RX-API-DMAC7.html)
DE (1) DE69633449T2 (cg-RX-API-DMAC7.html)
ES (1) ES2229281T3 (cg-RX-API-DMAC7.html)
IL (1) IL122803A0 (cg-RX-API-DMAC7.html)
MX (1) MX9800933A (cg-RX-API-DMAC7.html)
NO (1) NO980279D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ313864A (cg-RX-API-DMAC7.html)
WO (1) WO1997005195A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA966425B (cg-RX-API-DMAC7.html)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948768A (en) * 1995-04-13 1999-09-07 Milkhaus Laboratory Treatment of otitis media by sublingual administration of DNA
JP2961709B2 (ja) * 1995-04-13 1999-10-12 ミルカウス ラボラトリー， インコーポレイテッド 呼吸器系疾患の治療方法および治療用薬剤組成物
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
US6998121B2 (en) 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
PT1012154E (pt) 1997-07-25 2004-08-31 Inspire Pharmaceuticals Inc Sais de di(5'-tetrafosfato de uridina), metodo para a sua preparacao, e suas utilizacoes
ID29198A (id) * 1997-08-29 2001-08-09 Univ North Carolina Pemakaian uridin 5'-difosfat dan persamaannya untuk mengobati penyakit paru-paru
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
EP1139746A4 (en) * 1998-12-22 2003-09-17 Univ North Carolina CONNECTIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES AND THE ADMINISTRATION OF MEDICINAL SUBSTANCES
WO2000050024A2 (en) 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
AU782966B2 (en) * 1999-06-08 2005-09-15 University Of Iowa Research Foundation, The Compounds and methods to enhance RAAV transduction
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
WO2003000056A1 (en) 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Joint lubrication with p2y purinergic receptor agonists
JP3823162B2 (ja) * 2001-07-31 2006-09-20 株式会社エイアンドティー 臨床検査分析装置、臨床検査分析方法および臨床検査分析プログラム
MXPA04004215A (es) * 2001-11-06 2004-07-08 Inspire Pharmaceuticals Inc Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
US20060196365A1 (en) * 2001-12-11 2006-09-07 Garman Michael H Combined water cooler and hot beverage maker
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US20050220720A1 (en) * 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS
US7629312B2 (en) 2003-01-23 2009-12-08 Milkhaus Laboratory, Inc. Method of treatment of tendonitis by administration of streptolysin O
WO2004090145A2 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
BRPI0411900B8 (pt) 2003-06-26 2021-05-25 Biotron Ltd compostos e composições farmacêuticas compreendendo os mesmos
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
CA2547972A1 (en) * 2003-11-24 2005-06-09 Georgia State University Research Foundation, Inc. Fused ring dicationic anti-protozoan agents and their prodrugs
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070276020A1 (en) * 2004-03-08 2007-11-29 Boykin David W Dicationic Compounds For Activity Against Trichomonas Vaginalis
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
EP1874801A4 (en) 2005-03-07 2009-03-25 Univ North Carolina MEANS OF INHIBITING RECA ACTIVITIES FOR THE CONTROL OF ANTIBIOTIC-SITES BACTERIAL PATHOGENESE
AU2006201739A1 (en) * 2005-05-05 2006-11-23 The University Of North Carolina At Chapel Hill Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
EP1906922A2 (en) * 2005-05-18 2008-04-09 Pulmatrix, Inc. Formulations for alteration of biophysical properties of mucosal lining
US7964619B2 (en) 2005-06-03 2011-06-21 The University Of North Carolina At Chapel Hill Teraryl components as antiparasitic agents
AU2006202083A1 (en) * 2005-06-03 2006-12-21 Reto Brun Linear dicationic terphenyls and their aza analogues as antiparasitic agents
US20100249175A1 (en) * 2005-12-02 2010-09-30 Wilson W David Dicationic compounds which selectively recognize G-quadruplex DNA
EP2019964A2 (en) * 2006-04-28 2009-02-04 University of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection. method to identify a viral receptor or co-receptor
US20080260863A1 (en) * 2007-04-20 2008-10-23 Pre Holding, Inc. Compositions for mucociliary clearance and methods for administering same
AU2008266856A1 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of PFKFB3 inhibitors with anti-neoplastic activities
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US20100331368A1 (en) * 2007-10-17 2010-12-30 Tidwell Richard R 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents
MX2010011050A (es) 2008-04-09 2010-11-01 Univ North Carolina Metodos para regular el reodernamiento citoesqueletico de actina y la formacion de aberturas intercelulares.
AU2009298367A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
EP2341906A4 (en) * 2008-10-01 2012-06-13 Univ North Carolina HEMATOPOIETIC PROTECTION AGAINST IONIZATION RADIATION USING SELF-ACTIVE CYCLINE-DEPENDENT KINASE-4/6-HEMMER
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
EP3718560A3 (en) 2009-05-13 2020-12-09 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
WO2011008756A1 (en) 2009-07-13 2011-01-20 Irix Pharmaceuticals Synthesis of prostanoids
CA2768582C (en) 2009-07-24 2017-02-14 University Of Tennessee Research Foundation Spectinamides as anti-tuberculosis agents
WO2011018468A1 (en) * 2009-08-10 2011-02-17 P2-Science Aps Utp for the diagnosis of stenoses and other conditions of restricted blood flow
JP5922111B2 (ja) * 2010-06-23 2016-05-24 ピーツー−サイエンス・エペイエス 充血剤注入と同時に血圧測定を行う診断目的の動脈用複合カテーテル
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CA2812414C (en) 2010-09-29 2020-09-22 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
US9433576B2 (en) 2010-09-29 2016-09-06 Pulmatrix, Inc. Cationic dry powders
AU2011329763A1 (en) 2010-11-17 2013-05-09 Brigham And Women's Hospital Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
EP2717855A4 (en) * 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
JP2015509788A (ja) 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド 吸入に適した乾燥粉末
US9833207B2 (en) 2012-08-08 2017-12-05 William Harrison Zurn Analysis and clearing module, system and method
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
UA120343C2 (uk) 2012-12-17 2019-11-25 Періон Сайєнсіз, Інк. Похідні хлорпіразинкарбоксаміду, які мають активність блокування епітеліальних натрієвих каналів
US9962533B2 (en) 2013-02-14 2018-05-08 William Harrison Zurn Module for treatment of medical conditions; system for making module and methods of making module
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2014144847A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP2981247B1 (en) 2013-04-01 2023-06-07 Pulmatrix Operating Company, Inc. Tiotropium dry powders
CA2925927C (en) 2013-09-30 2022-09-06 George Petros Yiannikouros Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US20150297607A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN104306028B (zh) * 2014-09-26 2016-08-17 张清玲 一种用于呼吸道细菌16S rRNA基因序列检测的痰液收集方法
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
EP3426787A1 (en) 2016-03-07 2019-01-16 University of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
US10413583B2 (en) 2016-11-30 2019-09-17 The University Of Chicago Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
MX2019010381A (es) 2017-03-01 2020-01-21 Achillion Pharmaceuticals Inc Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
WO2019028284A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
GB2604314A (en) 2017-09-22 2022-09-07 Nerudia Ltd Device, system and method
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
AU2019406830A1 (en) 2018-12-17 2021-07-08 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055465A (en) * 1962-09-27 1967-01-18 Vantorex Ltd Allergenic aerosol compositions
BE639386A (cg-RX-API-DMAC7.html) * 1962-10-30
US4132600A (en) * 1977-06-01 1979-01-02 Massachusetts Institute Of Technology Enzymatic noninvasive method for detecting cancer
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
FR2571257A1 (fr) * 1984-08-06 1986-04-11 Gros Pierre Composition destinee a l'humidification de la muqueuse rhino-pharyngee
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US4950477A (en) * 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
US6214536B1 (en) 2001-04-10
EP0841900A1 (en) 1998-05-20
WO1997005195A1 (en) 1997-02-13
ATE276740T1 (de) 2004-10-15
MX9800933A (es) 1998-05-31
AU6639996A (en) 1997-02-26
EP0841900A4 (cg-RX-API-DMAC7.html) 1998-06-10
NO980279L (no) 1998-01-21
JP2003073280A (ja) 2003-03-12
CN1191553A (zh) 1998-08-26
IL122803A0 (en) 1998-09-16
ES2229281T3 (es) 2005-04-16
BR9610059A (pt) 1999-03-02
US6133247A (en) 2000-10-17
US5902567A (en) 1999-05-11
NZ313864A (en) 2000-04-28
JPH11509759A (ja) 1999-08-31
AU705528B2 (en) 1999-05-27
KR19990036011A (ko) 1999-05-25
NO980279D0 (no) 1998-01-21
JP3623237B2 (ja) 2005-02-23
EP0841900B1 (en) 2004-09-22
KR100283306B1 (ko) 2001-03-02
DE69633449T2 (de) 2006-04-27
CA2226892A1 (en) 1997-02-13
US5628984A (en) 1997-05-13
CN1121441C (zh) 2003-09-17
DE69633449D1 (de) 2004-10-28

Similar Documents

Publication Publication Date Title
ZA966425B (en) Method of detecting lung disease.
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
MXPA01008547A (es) Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
WO1997035591A3 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US6159952A (en) Method of treating bronchitis with uridine triphosphate and related compounds
MY120023A (en) Method of treating dry eye disease with uridine triphosphates and related compounds.
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
CA2223776A1 (en) Method of treatment for lung diseases using antisense oligonucleotides
ZA987847B (en) Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof
DE69533128D1 (de) Pharmazeutische akzeptabel dnase zusammensetzung
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
CA2147469A1 (en) Compaction assay for assessment of respiratory disease therapy
KR890012942A (ko) 5-치환된 오르니틴 유도체
AU3733295A (en) Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
Bishara et al. Lichenoid reaction in bone marrow transplants suffering from chronic GVHD is associated with HLA-DQW1
RU95120783A (ru) Способ профилактики и лечения атеросклероза
RU97110383A (ru) Способ профилактики и лечения атеросклероза
AU753972C (en) Low adenosine oligonucleotide, composition, kit and methods for obtaining oligonucleotide and for treatment of airway disease(s)